- Home
- Products
- Customized FluoroAb™
- EPHB2
- Anti-EPHB2 MAb (Clone 1)-iFluor® 488 Succinimidyl Ester
Anti-EPHB2 MAb (Clone 1)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9544)
- TARGET
- ANTIBODY
- DYE
- Name
- EPHB2
- Alternative Names
- EPHB2; Ephb2; Cek5; Drt; ETECK; Erk; Hek5; Nuk; Prkm5; Qek5; Sek3; Tyro5; CAPB; EK5; EPHT3; PCBC; EPH receptor B2; DRT; ERK; BDPLT22
- Overview
- Humanized Anti-EEPHB2 antibody (Clone 1)
- Species Reactivity
- Human
- Name
- iFluor® 488 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 491/516
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS9544. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-153 | Anti-EPHB2 -BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-FOLH1 MAb (Clone 2)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS300)
- Anti-CD4 MAb (Clone 29)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2700)
- Anti-MS4A1 MAb (Clone 24)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7048)
- Anti-CD79B MAb (Clone 6)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11092)
- Anti-TNFRSF8 MAb (Clone 12)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS15790)
- Anti-161P2F10B MAb (Clone 1)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS1768)
- Anti-SLC39A6 MAb (Clone 1)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5050)
- Anti-NGF MAb (Clone 11)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4516)
- Anti-EPCAM MAb (Clone 12)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS4826)
- Anti-TPBG MAb (Clone 2)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS10994)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.